OLMA

Olema Pharmaceuticals, Inc.

11.61 USD
-0.02 (-0.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Olema Pharmaceuticals, Inc. stock is up 28.15% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 3 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
04 Jun 19:03 18 Oct, 2024 15.00 CALL 118 4926
04 Jun 19:09 18 Oct, 2024 15.00 CALL 153 4926
04 Jun 19:09 18 Oct, 2024 15.00 CALL 93 4926
04 Jun 19:10 18 Oct, 2024 15.00 CALL 109 4926
04 Jun 19:10 18 Oct, 2024 15.00 CALL 171 4926
04 Jun 19:13 18 Oct, 2024 15.00 CALL 123 4926
04 Jun 19:13 18 Oct, 2024 15.00 CALL 85 4926
04 Jun 19:13 18 Oct, 2024 15.00 CALL 120 4926
04 Jun 19:13 18 Oct, 2024 15.00 CALL 106 4926
04 Jun 19:14 18 Oct, 2024 15.00 CALL 94 4926

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies for women's cancers. OP-1250, an estrogen receptor antagonist and a selective ER degrader, is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.